<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney Med</journal-id><journal-id journal-id-type="iso-abbrev">Kidney Med</journal-id><journal-title-group><journal-title>Kidney Medicine</journal-title></journal-title-group><issn pub-type="epub">2590-0595</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35765465</article-id><article-id pub-id-type="pmc">PMC9222403</article-id><article-id pub-id-type="pii">S2590-0595(22)00124-8</article-id><article-id pub-id-type="doi">10.1016/j.xkme.2022.100503</article-id><article-id pub-id-type="publisher-id">100503</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject><subj-group><subject>Letter to the Editor</subject></subj-group></subj-group></article-categories><title-group><article-title>In Reply to &#x02018;Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations&#x02019;</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Fernandes</surname><given-names>Guillaume</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Devresse</surname><given-names>Arnaud</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Scohy</surname><given-names>Anais</given-names></name><degrees>PharmD</degrees><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>De Greef</surname><given-names>Julien</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Yombi</surname><given-names>Jean Cyr</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Belkhir</surname><given-names>Leila</given-names></name><degrees>MD, PhD</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Darius</surname><given-names>Tom</given-names></name><degrees>MD, PhD</degrees><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Mourad</surname><given-names>Michel</given-names></name><degrees>MD, PhD</degrees><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Buemi</surname><given-names>Antoine</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Kabamba</surname><given-names>Benoit</given-names></name><degrees>PharmD, PhD</degrees><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Goffin</surname><given-names>Eric</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Kanaan</surname><given-names>Nada</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1</label>Division of Nephrology, Cliniques Universitaires Saint-Luc, Universit&#x000e9; Catholique de Louvain, Brussels, Belgium</aff><aff id="aff2"><label>2</label>Microbiology, Cliniques Universitaires Saint-Luc, Universit&#x000e9; Catholique de Louvain, Brussels, Belgium</aff><aff id="aff3"><label>3</label>Internal Medicine and Infectious Disease, Cliniques Universitaires Saint-Luc, Universit&#x000e9; Catholique de Louvain, Brussels, Belgium</aff><aff id="aff4"><label>4</label>Internal Medicine and Infectious Disease, and Abdominal Surgery and Transplantation, Cliniques Universitaires Saint-Luc, Universit&#x000e9; Catholique de Louvain, Brussels, Belgium</aff></contrib-group><pub-date pub-type="pmc-release"><day>23</day><month>6</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2022</year></pub-date><volume>4</volume><issue>8</issue><elocation-id>100503</elocation-id><permissions><copyright-statement>&#x000a9; 2022 The Authors</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><related-article related-article-type="article-reference" id="d35e14" ext-link-type="doi" xlink:href="10.1016/j.xkme.2022.100502"/></article-meta></front><body><p id="p0010">We thank Mungmunpuntipantip and Wiwanitkit<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> for their constructive comments. Among the 47 kidney transplant recipients included in this study, 17 had antihuman leukocyte antigen antibodies detected within 2 years prior to infection, but none had donor-specific antibodies.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Antihuman leukocyte antigen antibody status was not available for 6 patients. No patient was treated for acute rejection in the 2 years prior to infection.</p><p id="p0015">Eight kidney transplant recipients out of 47 had a history of documented SARS-CoV-2 infection. Among them, only 3 presented with positive antinucleocapside antibodies. Interestingly, 2 additional patients in the cohort had positive antinucleocapside antibodies without any prior documented infection. None of these kidney transplant recipients required hospitalization.</p><p id="p0020">We agree that this may have played a role in these patients&#x02019; recoveries as prior infection may reduce the risk of severe COVID-19.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> However, our cohort is too limited to draw conclusions on this. Moreover, to our knowledge, it is ill-defined whether prior infection that does not lead to a serologic response confers protection against severe COVID-19.</p></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Mungmunpuntipantip</surname><given-names>R.</given-names></name><name><surname>Wiwanitkit</surname><given-names>V.</given-names></name></person-group><article-title>Kidney transplant recipients with COVID-19 and monoclonal antibody therapy: additional considerations [letter]</article-title><source>Kidney Med</source><volume>4</volume><issue>8</issue><year>2022</year><fpage>100502</fpage><pub-id pub-id-type="pmid">35765466</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>G.</given-names></name><name><surname>Devresse</surname><given-names>A.</given-names></name><name><surname>Scohy</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Monoclonal antibody therapy in kidney transplant recipients with delta and omicron variants of SARS-CoV-2: a single-center case series</article-title><source>Kidney Med</source><volume>4</volume><issue>6</issue><year>2022</year><object-id pub-id-type="publisher-id">100470</object-id><pub-id pub-id-type="doi">10.1016/j.xkme.2022.100470</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>V.</given-names></name><name><surname>Foulkes</surname><given-names>S.</given-names></name><name><surname>Insalata</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection</article-title><source>N&#x000a0;Engl J Med</source><volume>386</volume><issue>13</issue><year>2022</year><fpage>1207</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">35172051</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Nordstr&#x000f6;m</surname><given-names>P.</given-names></name><name><surname>Ballin</surname><given-names>M.</given-names></name><name><surname>Nordstr&#x000f6;m</surname><given-names>A.</given-names></name></person-group><article-title>Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden</article-title><source>Lancet Infect Dis</source><volume>22</volume><issue>6</issue><year>2022</year><fpage>781</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00143-8</pub-id><pub-id pub-id-type="pmid">35366962</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Article Information</title><sec id="sec1"><title>Authors&#x02019; Contributions</title><p id="p0025">Drs Fernandes and Devresse contributed equally to this correspondence.</p></sec><sec id="sec2"><title>Financial Disclosure</title><p id="p0030">The authors declare that they have no relevant financial interests.</p></sec><sec id="sec3"><title>Peer Review</title><p id="p0035">Received May 25, 2022 in response to an invitation from the journal. Accepted June 03, 2022 after editorial review by the Editor-in-Chief.</p></sec></ack></back></article>
